^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + itacitinib (INCB039110) (JAK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P1.15-07 - Phase II Study of Pembrolizumab and Itacitinib for First Line Treatment of Metastatic NSCLC Expressing PD-L1
Published date:
07/12/2022
Excerpt:
Itacitinib 200mg daily po was started Cycle 3 Day 1 of pembrolizumab and continued for 6 weeks...Treatment-naïve pts with mNSCLC and PD-L1 expression ≥50% treated with pembrolizumab and a brief course of JAK inhibition starting at week 6 of treatment resulted in an ORR of 62% at 12 weeks and mPFS of 23.4 months.
